Shareholders in Dechra Pharmaceuticals (DPH) were the beneficiaries of a 24 per cent hike in the annual dividend, but it’s clear that the veterinary products group will also be looking to attract potential investors through an intensified focus on margins.
To continue reading, subscribe today
and enjoy unlimited access to the following:
- Tips of the Week
- Funds coverage
- Weekly features on big investment themes
- Trading ideas
- Comprehensive companies coverage
- Economic analysis
